on Bb Biotech (isin : CH0038389992)
BB Biotech AG Reports Q1 2026 Interim Results
BB Biotech AG has released its interim report for the first quarter of 2026. The investment company, headquartered in Schaffhausen, Switzerland, published that it recorded a net loss of CHF 21 million for the period ending March 31, 2026. This is a significant improvement compared to the CHF 241 million loss reported in the same quarter of the previous year, 2025.
The reported loss is largely attributed to the share price performance of companies within BB Biotech's investment portfolio. BB Biotech is one of the largest investors in innovative drug developers, particularly in the US and Western Europe. The interim report is accessible on their official website.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Bb Biotech news